Liu Xiaolin, Wang Jing, Xu Feng, Chen Jing, Zhu Mingyuan, Wang Xiaoguang
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Department of Digestive Endoscopy, The General Hospital of Northern Theater Command, Shenyang, China.
Cancer Med. 2025 May;14(9):e70806. doi: 10.1002/cam4.70806.
This study aimed to investigate the predictive value of the radiographic tumor burden score (TBS) for long-term outcomes in hepatocellular carcinoma (HCC) patients meeting Milan criteria after microwave ablation (MWA) and to delineate its significance in guiding treatment planning.
Retrospective analysis was conducted on clinical data from 198 HCC patients meeting Milan criteria, who underwent MWA at our hospital from January 2011 to December 2018. Using X-tile software, the optimal critical value of TBS was determined, leading to the categorization of patients into high- and low-TBS groups. Propensity score matching (PSM) was applied to balance covariates between these groups.
Before PSM, the 5-year overall survival (OS) rate and recurrence-free survival (RFS) rate in the high-TBS (47 cases) and low-TBS groups (151 cases) were 32.8% versus 59.7% (p = 0.033) and 23.4% versus 50.9% (p = 0.016), respectively. Following PSM, the 5-year OS rate and RFS rate in the high-TBS (44 cases) and low-TBS groups (95 cases) were 30.2% versus 64.1% (p = 0.011) and 21.9% versus 45.9% (p = 0.0059), respectively. Cox analysis identified high TBS and percutaneous microwave ablation (PMWA) as independent risk factors for OS and RFS. The stratified analysis revealed that the median RFS time for patients undergoing laparoscopic microwave ablation (LMWA) (20 cases) and PMWA (24 cases) in the high-TBS group (44 cases) was 45 and 10.5 months, respectively (p = 0.006).
TBS emerged as a robust predictor for the long-term outcomes of HCC within Milan criteria after MWA. A higher TBS was associated with a diminished long-term survival rate. Notably, among HCC patients meeting Milan criteria, those with TBS > 3 exhibited a prolonged median RFS time following LMWA compared to PWMA.
本研究旨在探讨放射学肿瘤负荷评分(TBS)对符合米兰标准的肝细胞癌(HCC)患者微波消融(MWA)后长期预后的预测价值,并阐明其在指导治疗计划中的意义。
对2011年1月至2018年12月在我院接受MWA的198例符合米兰标准的HCC患者的临床资料进行回顾性分析。使用X-tile软件确定TBS的最佳临界值,从而将患者分为高TBS组和低TBS组。应用倾向评分匹配(PSM)来平衡两组之间的协变量。
在PSM之前,高TBS组(47例)和低TBS组(151例)的5年总生存率(OS)和无复发生存率(RFS)分别为32.8%对59.7%(p = 0.033)和23.4%对50.9%(p = 0.016)。PSM后,高TBS组(44例)和低TBS组(95例)的5年OS率和RFS率分别为30.2%对64.1%(p = 0.)和21.9%对45.9%(p = 0.0059)。Cox分析确定高TBS和经皮微波消融(PMWA)是OS和RFS的独立危险因素。分层分析显示,高TBS组(44例)中接受腹腔镜微波消融(LMWA)(20例)和PMWA(24例)的患者的中位RFS时间分别为45个月和10.5个月(p = 0.006)。
TBS是符合米兰标准的HCC患者MWA后长期预后的有力预测指标。较高的TBS与较低的长期生存率相关。值得注意的是,在符合米兰标准的HCC患者中,TBS>3的患者在接受LMWA后的中位RFS时间比PWMA延长。